Ultimate Software Group

UUltimate Software’s UltiPro® cloud solutions for HR, payroll, and talent are inherently designed to improve the employee experience. Powered by Xander®, Ultimate’s portfolio of “People First” artificial intelligence technologies, UltiPro helps organizations develop highly productive and satisfied workforces. With UltiPro’s personalized recruiting and convenient onboarding capabilities, companies can make positive first impressions and establish long-term relationships. UltiPro makes it easy for HR to actively manage employee files—anytime, anywhere. Employees can access their personal, pay, and benefits information directly from UltiPro, and administrators can rapidly calculate and process accurate payroll. A flexible, configurable solution, UltiPro has workforce management tools to serve businesses of all sizes, and intuitive features and tools for ongoing compensation, performance, and succession management—from predicting top performers to building better leaders. UltiPro also offers a modern approach to learning that fosters career development, and organizations can use UltiPro’s advanced survey solutions to measure how employees truly feel about work. Plus, employees can get personalized, on-demand support for HR-related requests. Most importantly, UltiPro is supported by powerful business intelligence across its solutions to help drive smarter, people-focused results. Ultimate is committed to putting people first, always. This core principle drives its award-winning culture, products, and services—delivering a customer experience that’s personalized, proactive, and goes beyond software support. Founded in 1990 and based in Weston, Florida, Ultimate has ranked in the top 25 on Fortune’s 100 Best Companies to Work For since 2012. The company serves thousands of customers in diverse industries managing millions of people worldwide.

OSLO, Norway--(BUSINESS WIRE)---- $ULTI #ClinicalTrials--Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in Frontiers in Immunology of its positive long-term Overall Survival (OS) data from the Phase I trial evaluating the Company's universal cancer vaccine, UV1, in combination with checkpoint inhibitor ipilimumab in patients with metastatic malignant melanoma. As published in the journal, in addition to the achievement of the p

Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology

OSLO, Norway--(BUSINESS WIRE)---- $ULTI #1Q21--Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 results today. A presentation by the Company's management team will take place today on a webcast at 09:00 CEST. The presentation can be followed as a live webcast, which will also be available on our website. Highlights for the first quarter of 2021: In the INITIUM trial, 40 patients have been enrolled as per the r

Ultimovacs ASA: First Quarter 2021 Result Presentation

OSLO, Norway--(BUSINESS WIRE)---- $ULTI #ASCO--Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its management team will discuss data from the abstract of a poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting at a series of investor events in May, beginning with a live corporate webcast on Thursday May 20, 2021. The abstract is titled “A Phase I Clinical Trial Investigating the Telomerase Va

Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings

OSLO, Norway--(BUSINESS WIRE)---- $ULTI--Ultimovacs ASA ("Ultimovacs", ticker ULTI) today announced that an abstract on the Company's Phase I trial evaluating its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab in patients with metastatic malignant melanoma has been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting to be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021. The abstract, titled

Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting

OSLO, Norway--(BUSINESS WIRE)---- $ULTI #AACR2021--Ultimovacs ASA ("Ultimovacs", ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company's proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021. The poster, titled, “Nivolumab and ipilimumab

Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021

OSLO, Norway--(BUSINESS WIRE)---- $ULTI--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the Company's Tetanus-Epitope Targeting (TET)-platform. The platform allows for the production of multiple therapeutic cancer vaccines that can be used to strengthen and increase T cell responses to cancer cells by targeting antigens that are specific to one type of cancer or common to many tum

Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

OSLO, Norway--(BUSINESS WIRE)---- $ULTI #4Q20--Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its fourth quarter 2021 results today. A presentation by the company's management team will take place today on a webcast at 09:00 CET. The presentation can be followed as a live webcast, which will also be available on our corporate website. Highlights for the fourth quarter of 2020: Ultimovacs provided details about the DOVACC trial in

Ultimovacs ASA: Fourth Quarter 2020 Result Presentation

OSLO, Norway--(BUSINESS WIRE)---- $ULTI #DOVACC--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced its participation in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups (ENGOT) and AstraZeneca, to conduct a randomized Phase II clinical trial to evaluate Ultimovacs' proprietary universal cancer vaccine, UV1, in combination with AstraZeneca's durvalumab and olaparib

Ultimovacs Announces Phase II DOVACC Collaboration Study in Ovarian Cancer With the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca

OSLO, Norway--(BUSINESS WIRE)---- $ULTI #Phase1--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced positive five-year Overall Survival (OS) data from the Phase I trial evaluating the company's universal cancer vaccine, UV1, in combination with the checkpoint inhibitor, ipilimumab, in patients with metastatic malignant melanoma. After 5-years of follow-up, 50% of the patients in the open-label trial were still alive, providing encouraging signals of long-term survival benefit for UV1 in this late-stage

Ultimovacs Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma

Ultimate Software (ULTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Ultimate Software Group Stock (ULTI)